First Mid Bancshares, Inc. Announces Acquisition of Two Rivers Financial Group, Inc.

(NasdaqGM:FMBH),(Other OTC:TRVR), MATTOON, Ill. and BURLINGTON, Iowa, Oct. 30, 2025 (GLOBE NEWSWIRE) — First Mid Bancshares, Inc. (NASDAQ: FMBH) (“First Mid”) and Two Rivers Financial Group, Inc. (OTCQX: TRVR) (“Two Rivers”) announced the execution of a definitive agreement dated October 29, 2025 under which Two Rivers will merge with First Mid in a 100% stock […]

Australian Oilseeds Receives Approval to Transfer Listing to The Nasdaq Capital Market and Regains Compliance with Nasdaq Listing Requirements

Australian Oilseeds Receives Approval to Transfer Listing to The Nasdaq Capital Market and Regains Compliance with Nasdaq Listing Requirements GlobeNewswire October 30, 2025 COOTAMUNDRA, Australia, Oct. 30, 2025 (GLOBE NEWSWIRE) — Australian Oilseeds Holdings Limited (the “Company”) (NASDAQ: COOT), a manufacturer and seller of sustainable edible oils to customers globally, today announced it has received

Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET

(NasdaqGM:HBIO), HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on November 6, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join

Consumers Are Open to AI in Healthcare if Human-Guided & Transparent, New Zyter|TruCare Survey Reveals

Consumers Are Open to AI in Healthcare if Human-Guided & Transparent, New Zyter|TruCare Survey Reveals Survey showcases consumer attitudes towards health plans' use of AI GlobeNewswire October 30, 2025 Rockville, Maryland, Oct. 30, 2025 (GLOBE NEWSWIRE) — Consumers are cautiously optimistic about health insurers' use of artificial intelligence (AI), with most saying they would support

Solid Biosciences to Participate at Upcoming Investor Conferences

(NASDAQ:SLDB), CHARLESTOWN, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2025 Truist Securities BioPharma SymposiumDr. Gabriel Brooks, Chief Medical Officer, will participate in a panel discussion

New Sunrun Survey Finds Soaring Electricity Demand and Extreme Weather Are Fueling Homeowner Anxiety; 80% Fear Data Centers Will Drive Up Utility Prices

New Sunrun Survey Finds Soaring Electricity Demand and Extreme Weather Are Fueling Homeowner Anxiety; 80% Fear Data Centers Will Drive Up Utility Prices With the majority of Americans saying they feel unprepared for grid instability, electricity outages, and extreme weather, Sunrun offers peace of mind with home battery storage and solar GlobeNewswire October 30, 2025

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

(NASDAQ:LSTA), BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2025,

MediBeacon to Present at the Upcoming American Society of Nephrology (ASN) Kidney Week 2025

MediBeacon to Present at the Upcoming American Society of Nephrology (ASN) Kidney Week 2025 GlobeNewswire October 30, 2025 ST. LOUIS, Oct. 30, 2025 (GLOBE NEWSWIRE) — MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced that data from the Company's transdermal GFR technology has

23andMe Research Institute Appoints Privacy Advisory Board

PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — 23andMe Research Institute, a nonprofit medical research organization, today announced the formation of its Privacy Advisory Board. Composed of leading experts in health data privacy, data ethics, and consumer advocacy, the Board will provide strategic guidance on the protection of member information and the organization's responsible

New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire October 30, 2025 Three abstracts accepted for presentation, including one rapid oral abstract session Presentations to highlight ongoing clinical and translational research across PDS Biotechnology's

Scroll to Top